Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.

@article{Ljung2007EarlyCI,
  title={Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.},
  author={Tryggve Ljung and L Axelsson and Max Herulf and Jon O N Lundberg and Per M Hellstr{\"o}m},
  journal={Alimentary pharmacology & therapeutics},
  year={2007},
  volume={25 8},
  pages={925-32}
}
BACKGROUND Treatment with tumor necrosis factor-alpha monoclonal antibody (infliximab) reduces clinical activity and intestinal inflammation in Crohn's disease. AIM To study the time-course of the effects of infliximab with reference to mucosal cytokine and inducible nitric oxide synthase expression. METHODS Thirty-two patients with Crohn's disease were treated with single dose infliximab (5 mg/kg). Disease activity was assessed days 1, 3, 7 and 28 using Harvey-Bradshaw index. Rectal nitric… CONTINUE READING